Fresh analysis indicates that individuals who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide can put back on lost weight far faster than those who end conventional diet and exercise plans.
Published data in a prominent health publication shows that while obese individuals often shed a large proportion of their total mass while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"People purchasing these medications need to be informed of the risk of rapid weight regain when the therapy ends," stated lead investigator Dr. Susan Jebb.
That rate of regain means a reversion to original weight in about 18 months.
Analyzing Therapies
The analysis, which examined dozens of trials involving over 9,000 of participants, compared the outcomes of the injectable medications with conventional dieting.
Researchers point out that people who shed pounds through lifestyle changes alone typically have a slower weight regain—perhaps 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Experts suggest the way of the drugs explains the amplified weight return.
These medications copy a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of the hormone concentrations several times higher than normal may cause the body to produce less of its own natural GLP-1, and could reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating far more likely."
A Chronic Disease?
Health authorities recommend the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals argue that, due to the significant potential of weight regain, the treatment might need to be long-term.
This perspective is reinforced by pharmaceutical companies, who note that the results "emphasize the chronic nature of obesity," comparing it to managing conditions like hypertension.
Patient Testimonies
Users who have discontinued the jabs describe a powerful return of cravings.
"It was like a switch activating and you become starving," said an individual.
This challenge is compounded if users have not adopted sustainable lifestyle or habit modifications during therapy.
Widespread Use
Survey data indicate that millions of people in the UK have used these injections in the past year, with desire continuing to grow.
- Adoption is greater among women compared to men.
- The middle-aged age group shows the greatest usage rates.
- Many obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians caution that while GLP-1 drugs are effective agents for weight loss, they are not a permanent solution and lasting health benefits likely depends on ongoing lifestyle changes.
